Lupin Ltd

Lupin Ltd

₹ 1,633 1.04%
02 Jul - close price
About

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Key Points

Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]

  • Market Cap 74,442 Cr.
  • Current Price 1,633
  • High / Low 1,728 / 890
  • Stock P/E 32.0
  • Book Value 452
  • Dividend Yield 0.24 %
  • ROCE 14.2 %
  • ROE 11.9 %
  • Face Value 2.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Stock is trading at 3.61 times its book value
  • The company has delivered a poor sales growth of 5.25% over past five years.
  • Company has a low return on equity of 4.48% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
2,516 3,314 2,870 2,732 2,855 2,732 2,829 2,861 2,836 3,496 3,659 4,116 3,396
2,074 2,349 4,269 2,524 2,354 2,444 2,515 2,646 2,574 2,791 2,824 2,898 2,696
Operating Profit 442 965 -1,399 208 501 289 314 215 262 705 835 1,217 700
OPM % 18% 29% -49% 8% 18% 11% 11% 8% 9% 20% 23% 30% 21%
49 25 75 35 16 6 15 17 55 28 26 23 31
Interest 12 15 18 16 25 20 18 31 29 16 15 11 13
Depreciation 125 125 130 128 131 130 138 134 146 140 149 145 290
Profit before tax 354 849 -1,472 100 362 145 173 67 142 577 696 1,084 428
Tax % 11% 24% 10% -431% 110% 19% 14% 40% 16% 17% 21% 15% 10%
316 646 -1,329 530 -36 117 149 40 119 477 549 916 384
EPS in Rs 6.97 14.23 -29.27 11.68 -0.79 2.58 3.27 0.89 2.62 10.48 12.05 20.13 8.43
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
7,122 8,939 9,752 11,344 12,626 10,081 11,356 11,026 11,056 11,772 11,259 14,666
5,224 6,016 6,375 7,357 8,134 7,992 8,504 9,116 9,012 11,560 10,295 11,207
Operating Profit 1,898 2,922 3,377 3,987 4,492 2,089 2,853 1,909 2,044 211 964 3,459
OPM % 27% 33% 35% 35% 36% 21% 25% 17% 18% 2% 9% 24%
9 405 177 187 82 128 -49 -286 129 215 210 107
Interest 33 21 5 24 29 33 35 53 41 73 98 56
Depreciation 150 168 337 306 366 390 426 519 503 514 548 725
Profit before tax 1,724 3,139 3,212 3,844 4,179 1,794 2,342 1,052 1,630 -162 527 2,785
Tax % 27% 26% 25% 26% 25% 25% 34% 31% 23% -17% 19% 16%
1,260 2,324 2,397 2,831 3,141 1,345 1,539 728 1,259 -189 425 2,326
EPS in Rs 28.16 51.84 53.34 62.83 69.56 29.74 34.01 16.06 27.74 -4.15 9.35 51.05
Dividend Payout % 14% 12% 14% 12% 11% 17% 15% 37% 23% -96% 43% 16%
Compounded Sales Growth
10 Years: 5%
5 Years: 5%
3 Years: 10%
TTM: 30%
Compounded Profit Growth
10 Years: 0%
5 Years: 6%
3 Years: 24%
TTM: 466%
Stock Price CAGR
10 Years: 4%
5 Years: 17%
3 Years: 12%
1 Year: 83%
Return on Equity
10 Years: 11%
5 Years: 5%
3 Years: 4%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 90 90 90 90 90 90 90 91 91 91 91 91
Reserves 4,757 6,889 8,938 11,823 14,690 15,695 17,027 17,383 18,475 18,059 18,321 20,512
669 144 45 392 593 17 6 6 485 951 749 105
1,530 1,675 1,935 1,931 2,475 2,879 2,567 3,201 2,808 3,212 3,523 4,215
Total Liabilities 7,046 8,799 11,008 14,236 17,848 18,681 19,690 20,680 21,859 22,313 22,684 24,923
2,014 2,179 2,036 2,345 3,013 3,341 3,373 3,514 3,639 3,690 4,022 4,148
CWIP 240 267 490 624 481 1,171 1,199 822 951 947 927 411
Investments 688 1,164 3,444 3,741 6,914 5,363 7,388 7,456 9,563 9,511 9,974 11,581
4,104 5,189 5,038 7,526 7,441 8,806 7,730 8,888 7,706 8,165 7,761 8,783
Total Assets 7,046 8,799 11,008 14,236 17,848 18,681 19,690 20,680 21,859 22,313 22,684 24,923

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,008 1,528 2,852 917 4,352 209 3,111 2,219 1,570 151 1,794 2,504
-372 -447 -1,178 -2,629 -1,941 725 -2,865 -740 -2,508 -372 -1,269 -1,599
-635 -844 -221 17 -160 -987 -295 -368 -53 102 -498 -867
Net Cash Flow 1 237 1,452 -1,696 2,252 -52 -50 1,112 -991 -118 27 38

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 96 117 94 146 113 179 120 120 105 84 87 96
Inventory Days 193 174 211 214 232 229 216 216 236 260 230 216
Days Payable 126 124 126 126 161 150 118 136 104 110 119 148
Cash Conversion Cycle 163 166 179 234 184 258 218 199 237 234 197 163
Working Capital Days 123 138 116 181 144 219 171 154 158 151 132 137
ROCE % 34% 50% 40% 36% 30% 11% 16% 10% 9% -1% 3%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
46.84% 46.83% 46.81% 46.78% 47.10% 47.11% 47.10% 47.08% 47.07% 47.06% 47.04% 47.01%
18.60% 15.66% 15.28% 14.65% 14.27% 13.81% 13.98% 13.32% 13.93% 14.99% 16.11% 18.29%
21.81% 24.47% 24.83% 26.91% 26.89% 27.63% 29.39% 28.92% 29.08% 29.14% 29.72% 27.76%
0.28% 0.28% 0.28% 0.29% 0.29% 0.00% 0.00% 0.28% 0.28% 0.28% 0.01% 0.01%
12.47% 12.76% 12.79% 11.37% 11.45% 11.45% 9.51% 10.39% 9.62% 8.52% 7.10% 6.93%
No. of Shareholders 3,02,2923,61,2883,61,8623,78,5473,82,8283,78,0113,60,6773,48,1493,22,6782,89,0742,81,5422,80,248

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls